1 Serum Vitamin D levels are associated with increased COVID-19

2 severity and mortality independent of visceral adiposity

Pablo Esteban Vanegas-Cedillo^{1,2}, Omar Yaxmehen Bello-Chavolla^{1,3}, Natalia RamírezPedraza⁴, Bethsabel Rodríguez Encinas^{2,} Carolina Isabel Pérez Carrión², María Isabel
Jasso Ávila², Jorge Carlos Valladares García², Diana Hernández-Juárez², Arsenio VargasVázquez, MD^{1,4}, Neftali Eduardo Antonio-Villa^{1,4}, Monica Chapa-Ibarguengoitia⁵, Alfredo
Ponce de Leon⁶, José Sifuentes-Osornio^{7,8} Carlos A. Aguilar-Salinas^{1,8,9}, Roopa Mehta^{1,2*}

8

¹Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias
Médicas y Nutrición Salvador Zubirán (INCMNSZ). ²Department of Endocrinology and
Metabolism, INCMNSZ, ³Research Division, Instituto Nacional de Geriatría. ⁴MD/PhD
(PECEM) program, Faculty of Medicine, National Autonomous University of Mexico.
⁵Department of Radiology, INCMNSZ, ⁶Department of Infectious Diseases, INCMNSZ,
⁷Internal Medicine Division, INCMNSZ ⁸Instituto Tecnologico y de Estudios Superiores de
Monterrey Tec Salud, ⁹Division of Nutrition, INCMNSZ.

16 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

17 *Correspondence: Roopa Mehta

18 Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias

- 19 Médicas y Nutrición Salvador Zubirán/ Department of Endocrinology and Metabolism,
- 20 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.
- 21 Tel +52 (55), 54 87 09 00, 2405. Email: roopamehta@yahoo.com
- 22 3,105 text words; 38 references; 4 tables; 3 figures.
- 23 Abstract: 230 words
- 24 **Running headline:** Vitamin D, adverse COVID-19 outcomes and adiposity

25 ABSTRACT (229 WORDS)

INTRODUCTION: Coronavirus disease (COVID-19) is a global pandemic. Vitamin D (25-OHD) deficiency has been associated with susceptibility to infectious disease. In this study, the association between COVID-19 outcomes and 25-OHD levels in patients attending a COVID-19 reference center in Mexico City are examined.

30 METHODS: Consecutive patients with confirmed COVID-19 were evaluated. All patients 31 underwent clinical evaluation (including outcomes), laboratory measurements (including 32 25-OHD) and a thoracic computerized tomography (including the measurement of 33 epicardial fat thickness). Low vitamin D was defined as levels <20ng/mL (<50nmol/L) and 34 severely low (or deficient) 25-OHD as a level ≤12ng/mL (<30nmol/L)</p>

35 **RESULTS:** Of the 551 patients included, low 25-OHD levels were present in 45.6% and 36 severely low levels in 10.9%. Severely low 25-OHD levels were associated with mortality 37 (HR 2.11, 95%CI 1.24-3.58, p=0.006) but not with critical COVID-19 (OR 0.97, 95%CI 38 0.94-0.99, p=0.042), adjusted for age, sex, body-mass index and epicardial fat. Using 39 model-based causal mediation analyses the increased risk of COVID-19 mortality 40 conferred by 25-OHD levels was partly mediated by its effect on D-dimer and cardiac 41 ultrasensitive troponins. Notably, increased risk of COVID-19 mortality conferred by low 42 vitamin D levels was independent of BMI and epicardial fat.

43 CONCLUSION: Vitamin D deficiency (≤12ng/mL or <30nmol/L), is independently
44 associated with COVID-19 mortality after adjustment for visceral fat (epicardial fat
45 thickness). Low 25-OHD may contribute to a pro-inflammatory and pro-thrombotic state,
46 increasing the risk for adverse COVID-19 outcomes.

47 **Keywords:** Vitamin D, COVID-19, SARS-CoV-2, Adiposity, Severe disease

48 **INTRODUCTION**

49 Coronavirus Disease (COVID-19), caused by the novel coronavirus severe acute 50 respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic. SARS-CoV-2 51 spreads primarily by close contact with respiratory droplets from infected individuals and 52 contaminated surfaces (1-3). SARS-CoV-2 infects cells using the angiotensin converting 53 enzyme-2 (ACE-2) receptor; infection can produce an interstitial pneumonia that may 54 progress to acute respiratory distress syndrome (ARDS) and death (4-6).

55 Vitamin D (25-OHD) is a steroid hormone involved in essential physiological roles 56 including preserving bone integrity, immunomodulation by stimulating innate immunity and 57 tempering adaptive immunity, infectious disease prevention and cardiovascular health (7-58 9). It also acts on the renin angiotensin aldosterone (RAAS) system, inhibiting the 59 angiotensin converting enzyme (ACE, 6). Several factors are known to influence vitamin D 60 levels; lower levels are associated with ethnicity, variation in sun exposure due to higher 61 latitudes, season, time of day, clothing, sunscreen use and skin pigmentation, age, lower 62 sun exposure, obesity and chronic illnesses (10). The presence of obesity results in 63 decreased bioavailability of vitamin D, which is probably related to sequestration into 64 adipose tissue. Furthermore, higher visceral fat content has been shown to be related to a 65 higher incidence of vitamin D deficiency (11).

Low levels of 25-OHD have been associated with increased susceptibility to infectious disease, particularly respiratory tract infections (12-14). Several studies have explored the relationship between COVID-19 and vitamin D levels (15-18); however, concerns regarding residual confounding and the lack of mechanistic interpretations for the association of low 25-OHD levels with adverse COVID-19 outcomes requires further studies. Obesity and ethnicity are important risk factors for severe disease, and are also known to modulate vitamin D levels. This may be particularly relevant in Mexico, where

high rates of diabetes and obesity have been associated with an increased risk of severe COVID-19 (19). In this study, the association between COVID-19 outcomes and 25-OHD levels in patients attending a COVID-19 reference center in Mexico City is evaluated. We aim to identify determinants of 25-OHD levels in COVID-19 patients and develop causalmediation models to propose mechanisms by which Vitamin D may lead to increased COVID-19 mortality.

79 **METHODS**

80 Study population

81 This study included consecutive patients evaluated at the Instituto Nacional de Ciencias 82 Médicas y Nutrición Salvador Zubirán, a COVID-19 reference center in Mexico City 83 between 17th March and 31st May 2020. Subjects were initially assessed at triage and 84 required either ambulatory or in-hospital care for COVID-19 (confirmed with computerized 85 tomography (CT) and/or via RT-gPCR test from nasopharyngeal swabs. All patients had 86 moderate to severe disease as defined by National Institute of Health criteria (Moderate 87 Illness: Evidence of lower respiratory disease during clinical assessment or imaging and 88 who have saturation of oxygen (SpO₂) ≥94% on air. Severe Illness: SpO₂ <94% on air, a 89 ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO_2/FiO_2) <300 90 mm Hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%). Subjects 91 underwent a chest CT, and a radiologist determined the degree of pulmonary parenchymal 92 disease and assessed epicardial fat thickness as a proxy for visceral fat. In addition, a 93 medical history, anthropometric measurements and laboratory tests were obtained, 94 including 25 hydroxy-vitamin D (25(OH)-D). The electronic files of each patient were 95 reviewed to document the outcomes during hospitalization. All proceedings were approved 96 by the research and ethics committee of the INCMNZ (Ref 3383) and informed consent 97 was waived due to the nature of the study.

98 Laboratory and clinical measurements

99 Clinical variables and laboratory measures were obtained at the time of initial evaluation. 100 Physical examination included: weight, height, body mass index (BMI, calculated as weight 101 in kilograms divided by squared height in meters), pulse oximeter saturation (SpO2), 102 respiratory rate (RR), temperature and arterial blood pressure (BP). Laboratory 103 measurements included: full blood count and chemistry panel including liver function tests, 104 C-reactive protein (CRP), fibrinogen, D-dimer, ferritin, troponin I (TPNI), erythrocyte 105 sedimentation rate (ESR) and procalcitonin levels. The blood samples were processed in 106 the central laboratory of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador 107 Zubirán, Vitamin D (25-hydroxivitamin D) was measured by chemiluminescence using the 108 Abbott Architect I2000 equipment. Low levels of vitamin D were defined as <20ng/mL (<50 109 nmol/L) and severely low (or deficiency) as a level <12ng/mL (<30nmol/L) (6-9).

110 Epicardial fat measurements

111 All patients underwent unenhanced CT scans including low-dose CT and two ultra-low-112 dose CT protocols with commonly reported imaging features of COVID-19 pneumonia. 113 The thoracic CT was performed using a 64-slice scanner (GE MEDICAL SYSTEMS 114 Revolution EVO). Epicardial adipose tissue (EAT) thickness was measured at 3 points 115 (right atrioventricular fossa, left atrioventricular fossa, and anterior interventricular fossa) in 116 the reformatted 4-chamber view using the multiplanar reconstruction (MPR) tool on the 117 workstation (20, 21, 22). The maximum thickness of the EAT was determined from the 118 surface of the myocardium to the pericardium (measured perpendicular to the 119 pericardium). The measurements were made on 2 different occasions, obtaining a total of 120 6 measurements; the average of them was used for all statistical analyses. Pericardial 121 adipose tissue (PAT) was quantified with the volume measurement tool with the 122 Carestream system of the workstation. The thickness of the thoracic subcutaneous

adipose tissue (TscAT) was measured from the anterior border of the sternum to the skin, at the level of the mitral valve in the axial plane of the tomography. The 80th genderspecific percentile of EAT thickness was obtained and used as the threshold to define increased EAT thickness. In addition, chest CT findings were recorded and used to evaluate severity of COVID infection.

128 COVID-19 outcomes

Outcomes included mortality and critical disease (defined as the combination of mortality and need for mechanical ventilation /intubation). For time-to-event analyses, time from self-reported symptom onset prior to evaluation until last follow-up (censoring) or death, whichever occurred first was estimated.

133 Statistical analyses

Cases with low and severely low vitamin D levels were analyzed using Student's t-test or Mann-Whitney U according to the variable distribution (parametric or non-parametric) for continuous variables. The chi-squared test was applied for categorical variables. Logarithmic, squared root and cubic root transformations were carried out to ensure variable symmetry prior to modeling. All statistical analyses were conducted using R 4.0.2.

139 Prediction of mortality and severe COVID-19

Cox proportional risk regression analyses was used to investigate the association of vitamin D with mortality related to COVID-19. Univariate models and fully adjusted models were generated which included the following covariates: age, gender, BMI, C-reactive protein, D-dimer, ultrasensitive cardiac troponin, epicardial fat, T2D, CKD and oxygen saturation levels. An interaction effect was explored with BMI or BMI categories to rule out the differential impact of vitamin D adjusted for BMI. Model diagnostics were done using Schoenfeld residuals. Finally, the association of vitamin D with requirement for mechanical

ventilation or the composite of critical COVID-19 was explored using logistic regressionanalyses adjusted for the aforementioned covariates.

149 Predictors of vitamin D levels

Linear regression analyses were fitted to identify predictors of log-transformed vitamin D levels in patients with COVID-19, and model selection was carried out using minimization of the Bayesian Information Criterion (BIC). Logistic regression models were also fitted using a dummy variable which defined low and severely low vitamin D to identify predictors for these categories and again model selection was conducted using BIC. Finally, model diagnostics for linear regression were conducted using residual analyses and the Hosmer-Lemeshow test for logistic regression analyses.

157 Causal mediation models

158 Finally, to explore whether variables which are influenced by Vitamin D levels may act as a 159 mediator of the risk conferred by Vitamin D on COVID-19 severity, model-based causal 160 mediation analyses were developed: D-dimer and ultrasensitive cardiac troponins were 161 proposed as mediators of the effect of Vitamin D on COVID-19 mortality. All mediation 162 analyses were performed using the mediation R package; to permit inference to obtain a 163 95% confidence interval using bias-corrected accelerated non-parametric bootstrap. To 164 demonstrate the sequential ignorability assumption, a sensitivity analysis was run to 165 demonstrate residual confounding by varying the correlation between the residuals of both 166 the outcome and the moderator models. Statistical analyses were performed using R 167 software version 4.0.3. A p value <0.05 was considered statistically significant

168 **RESULTS**

169 Study population

This study included 551 patients with confirmed COVID-19 (with compatible computerized
tomography findings and/or positive RT-qPCR test from nasopharyngeal swabs) and

172 vitamin D measurements. The mean age of participants was 51.92±13.74 years, with a 173 male predominance (n=355, 64.4%), and a mean BMI of 30.05±5.72. Median follow-up 174 was 15.0 days (IQR 10.0-20.0) and 445 patients required hospitalization (81.1%). Overall, 175 93 patients received invasive mechanical ventilation (16.88%) and 116 in-hospital deaths 176 (21.1%) were recorded. Type 2 diabetes (T2D) was present in 146 patients (26.9%), 219 177 patients had obesity (42.7%) and 217 were overweight (42.4%). Mean vitamin D levels 178 were 21.78±9.01 and vitamin D levels below 20ng/mL were present in 251 subjects 179 (45.6%) (Table 1). Extremely low vitamin D levels (≤12ng/mL) were observed in 59 180 patients (10.7%) (Table 1 supplementary material).

181 Determinants of Vitamin D levels amongst patients with COVID-19

182 The pathophysiological adaptations to COVID-19 may be predictive of low vitamin D 183 levels. To this end, determinants of low vitamin D in COVID-19 were sought in an attempt 184 to develop a mechanistic explanatory model for this relationship. Subjects with low vitamin 185 D levels (<20mmg/dl) were more likely to be female, have type 2 diabetes, higher HbA1c, 186 D-dimer and ferritin levels and lower oxygen saturation, albumin and C-reactive protein. 187 Using linear regression, a lower log-transformed vitamin D level was independently 188 associated with female gender, higher log-transformed ultrasensitive cardiac troponin, 189 higher log-transformed D-dimer, higher log-transformed epicardial fat area, and lower C-190 reactive protein levels (**Table 2**). When exploring a model to detect low vitamin D levels. 191 there was a significantly higher odds for log-transformed D-dimer levels (OR 1.31, 95%CI 192 1.06-1.63); lower odds were associated with male gender (OR 0.45, 95%Cl 0.31-0.65), 193 higher oxygen saturation levels (OR 0.98, 95%CI 0.97-0.99) and higher C-reactive protein 194 values (OR 0.75, 95%CI 0.61-0.92), adjusted for age, and log-transformed epicardial fat. 195 There was no association between days from symptom onset and vitamin D levels at 196 admission.

197 Vitamin D levels and COVID-19 mortality

198 Overall, vitamin D levels were significantly lower when comparing non-fatal to fatal COVID-199 19 cases (22.41±9.34 vs. 19.44±67.19, p<0.001). When assessing risk related to the 200 association between mortality and vitamin D levels using Cox regression, a 1-unit increase 201 in vitamin D levels was associated with a decreased risk of COVID-19 mortality. 202 Interestingly, when stratifying cases according to gender, the difference in vitamin D levels 203 between fatal and non-fatal cases was greater in women compared to men and lower in 204 cases with obesity (Figure 1). When the mortality models were adjusted for age, gender, 205 BMI, and C-reactive protein, CKD and T2D the observed association between vitamin D levels and a decrease in COVID-19 mortality persisted (Table 3). There was no significant 206 207 interaction with BMI, (as a continuous variable or categorized) in normal weight, 208 overweight and obese with vitamin D levels. Using post-estimation simulation to predict 209 risk associated with changes in vitamin D levels using the simPH R package, there was a 210 steady decrease in risk attributable to increasing vitamin D concentrations using vitamin D 211 <20ng/mL and ≤12ng/mL as thresholds (Figure 2).

212 Vitamin D and critical COVID-19

When assessing the impact of vitamin D on the risk of invasive mechanical ventilation there was no significant association even after adjustment for age, gender, BMI, C-reactive protein, CKD or T2D status (OR 0.986, 95%CI 0.957-1.015, p=0.366). However, when assessing the composite of critical COVID-19 using logistic regression models, lower vitamin D levels were associated with critical COVID-19 (OR 0.97, 95%CI 0.94-0.99, p=0.042, adjusting by age, gender, BMI, C-reactive protein, D-dimer, CKD, SpO2 or T2D status).

220 Causal mediation models

221 Finally, model-based causal mediation models were developed to assess whether the 222 effect of vitamin D (E) on increased mortality risk (Y) was mediated through changes in 223 variables identified in Table 2 (M), adjusted for age, gender, BMI and epicardial fat. The 224 direct effect of vitamin D on increased mortality risk was significant ($\Delta_{F \rightarrow Y}$ -0.144, 95%Cl -225 0.069, -0.010) and the indirect effect of vitamin D, mediated by increase D-dimer levels 226 $(\Delta_{E \to MY}$ -0.035, 95%Cl -0.164, -0.010), represented 19.3% (95%Cl 9.5-77.0%) of the 227 overall association of vitamin D on mortality. A similar scenario was observed for cardiac 228 troponins, whereby both the direct effect of vitamin D on mortality ($\Delta_{F \rightarrow Y}$ -0.133, 95%Cl -229 0.150, -0.020) and the indirect effect mediated by ultrasensitive cardiac troponins ($\Delta_{F \rightarrow MY}$ -230 0.047, 95%CI -0.085, -0.020), were significant and represented 26.2% (95%CI 14.9-231 73.0%) of the overall effect of vitamin D on mortality. Notably, there were no significant 232 causal mediation models for either BMI or epicardial fat, here there was only a direct effect 233 on mortality, independent of vitamin D levels.

234 **DISCUSSION**

235 In this study, the association between vitamin D levels and severity of COVID-19 was 236 explored in a Mexican population. Severely low levels of vitamin D (deficiency) showed a 237 clear association with mortality, even after adjusting for confounders, including epicardial 238 fat as a proxy of visceral fat and BMI. A vitamin D level <20ng/mL (<50nmol/L), showed a 239 strong negative predictive value, suggesting that when levels are adequate, the probability 240 of mortality is low. Furthermore, the increased risk of mortality from COVID-19 was partly 241 mediated by the effect of vitamin D on markers of disease severity, such as D-dimer and 242 ultrasensitive cardiac troponins, independent of BMI and epicardial fat (these showed 243 effects on COVID-19 mortality independent of vitamin D levels). This suggests that vitamin 244 D may be a marker of an impaired response to infection within the pulmonary epithelium, 245 in particular in those with severe deficiency (23).

246 Several studies have explored the relationship between COVID-19 and vitamin D levels 247 (15-17, 24). These include those examining vitamin D levels and risk of infection and those 248 examining an association with severity of COVID-19. Higher levels of IL-6 were observed 249 in the vitamin D deficient group suggesting a greater inflammatory response in these 250 patients (18). A recent systematic review and meta-analysis reported that vitamin D 251 deficiency was not associated with increased risk of infection, but severe cases presented 252 with greater vitamin D deficiency compared with mild cases. Vitamin D deficiency has 253 been associated to increased hospitalization and mortality risk from COVID-19 (19).

254 Physiological mechanisms by which vitamin D exerts a protective function include 255 enhanced innate immunity including augmentation of physical barriers to infection and 256 optimization of adaptive immunity (25). Adequate vitamin D levels favor protective tissue 257 maintenance, preserving tight, gap and adherens junctions, all of which are disturbed by 258 viruses (26). Calcitriol (1,25 OH D) induces production of cathelicidins, LL-37 and beta-259 defensins, proteins associated with viral surface disruption and reduced viral replication 260 rates, lower pro-inflammatory cytokine (e.g. tumor necrosis factor alpha, interleukin-6) 261 accumulation in target tissues such as the lungs and increased anti-inflammatory cytokine 262 concentrations that defend against viral infections (27). In addition, vitamin D enhances 263 macrophage phagocytosis and efferocytosis (allowing removal of cellular debris preventing 264 further inflammation), and regulation of the macrophage oxidative burst (eliciting a more 265 potent and efficient oxidative surge) (24).

Vitamin D also has a modulatory effect on the inflammatory response caused by COVID-19. It curbs adaptive immunity by inhibiting B cell proliferation, differentiation and production of antibodies and plays a role in regulation the T cell phenotype (28). Vitamin D suppresses helper T cells (Th)1 proliferation, thus decreasing the synthesis of cytokines such as interferon-gamma, interleukin-2 and interleukin-10 (6) (27, 29) This reduction in

271 cytokines, suppresses antigen presentation on dendritic cells and diminishes T lymphocyte 272 recruitment and proliferation. Thus, there is a shift in the adaptive immune response from 273 Th1 to a more regulatory Th2 response, characterized by an increase in expression of Th2 274 associated cytokines (IL-4, IL-10) (30, 31). This may attenuate the quantity of pro-275 inflammatory cytokines that are associated with severe infection (32) In addition, vitamin D 276 induces ACE 2 expression, and suppresses the angiotensin-renin system, thus reducing 277 levels of proinflammatory angiotensin II. Hence, vitamin D deficiency, could potentiate the 278 cytokine storm perpetuating a pro-inflammatory state and worsening pulmonary outcomes 279 (33). Finally, thrombotic complications are common in such patients; vitamin D is also 280 involved in the regulation of thrombotic pathways (29). In our study, low vitamin D levels in 281 COVID-19 patients were related to inflammatory, pro-thrombotic and metabolic markers of severity, confirming observations from previous studies. 282

283 Adverse COVID-19 outcomes have been linked to the ethnic origin of the population under 284 study; this has also been associated with the presence of vitamin D deficiency. Asians, 285 African Americans, and ethnic minorities are at an increased risk of mortality from COVID-286 19 (34). This may partly be due to a decrease in the production of vitamin D dependent on 287 UV rays. This is related to the skin levels of melanin present in these populations and on 288 the unequal distribution of poverty and cardiometabolic disease rates across such 289 ethnicities. This finding is relevant and may explain lower vitamin D levels and severity of 290 COVID-19 in México in a previous study (35). Previous reports in similar populations, 291 including Hispanics, have shown higher risk of SARS-CoV-2 infection, compared to 292 Caucasian population (36).

293 Currently, routine vitamin D supplementation in hospitalized patients with COVID-19 is not 294 recommended (37). A recent pilot study showed that administration of a high dose of 295 calcifediol or 25-hydroxyvitamin D, significantly reduced the need for intensive care in

hospitalized patients (38). The authors speculate that calcifediol may reduce severity of the disease. Ideally, additional large randomized controlled trials are needed to properly assess this claim and whether vitamin D supplementation can significantly impact population risk.

300 This study has certain strengths and limitations. It included a large number of patients with 301 heterogenous risk profiles in whom a variety of disease severity parameters were 302 measured. In addition, a series of statistical tests were carried out to ensure minimal 303 possibility of residual confounding. Nevertheless, some limitations must be acknowledged 304 in order to properly interpret this study. First, a chemiluminescence immunoassay was 305 used to assess vitamin D levels, this may lead to inconsistent results compared to other 306 techniques including competitive binding protein - CBP, radioimmunoassay - RIA liquid 307 chromatography - LC, UV detection with liquid chromatography and liquid chromatography 308 mass spectrometry LCMS or tandem mass spectrometry. Since most patients were 309 attended in the institution for the first time for COVID-19, historic vitamin D values were not 310 available to assess the effect of vitamin D dynamics on infection risk or outcomes. 311 Furthermore, given the disease course of COVID-19, severity profiles are highly 312 heterogeneous even amongst hospitalized patients, which may influence vitamin D values 313 on the basis of varying severity; control for this factor using propensity score matching was 314 carried out, however, there remains a possibility for residual confounding. Notably, these 315 results are from a COVID-19 reference center in Mexico City, this could reduce the 316 representativeness of the findings. Further evidence in other regions of Mexico to confirm 317 the role of vitamin D as a marker of disease severity and mortality in Mexicans with 318 COVID-19 is needed.

319 Conclusions

Vitamin D levels lower or equal to 12 ng/ml (30nmol/L) are independently associated with COVID-19 mortality, even after adjusting for confounders (including measures of visceral and total body fat). No association was confirmed between vitamin D levels and the need for intubation. Vitamin D deficiency is more prevalent in women and patients with type 2 diabetes mellitus. Vitamin D supplementation may be considered in deficient patients, but evidence of benefit is required from double blind randomized controlled trials.

328 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

- 329 **DATA AVAILABILITY:** Data is available from the corresponding author upon reasonable
- request. Code for reproducibility of results available at:
 https://github.com/oyaxbell/covid_metabolism
- **FUNDING:** This research did not receive any specific grant from funding agencies in the
- 333 public, commercial, or not-for-profit sectors.

334 ACKNOWLEDGMENTS

All authors approved the submitted version. All the authors would like to thank the staff of the Endocrinology and Metabolism Department for all their support. We are thankful to the study volunteers for all their work and support throughout the realization of the study. AVV, and NEAV are enrolled in the PECEM program at the Faculty of Medicine of UNAM; AVV and NEAV are supported by CONACyT. **CONTRIBUTIONS:** research idea and study design: RM, OYBC, CAAS; data acquisition:

RM, PEVC, NRP, MAJA, CIPC, BRE, JCVG, CAAS; data analysis/interpretation: OYBC, RM, CAAS, NEAV, AVV; statistical analysis: OYBC, NEAV; manuscript drafting: RM, OYBC, NEAV, AVV, CAAS; supervision or mentorship: RM, CAAS, APL, JSO. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

347

349 **REFERENCES**

- CDC, How COVID-19 Spreads. https://www.cdc.gov/coronavirus/2019-ncov/preve
 nt-getting-sick/how-covid -spreads.html. 2020
- Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on
 coronavirus disease 2019 (COVID-19) outbreak an update on the status. Mil Med
 Res. 2020;7(1):11
- 355 3. Huang C, Wang Y, Li X, Ren L, et al. Clinical features of patients infected with
 2019 novel coronavirus in Wuhan. China Lancet Lond Engl. 2020;395:497-506
- 4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor
 binding. Lancet. 2020; 395(10224):565–574.
- 5. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with
 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
 observational study. Lancet Respir Med. 2020;8: 475-481.
- 363
 6. Mahdavi A M. A brief review of interplay between vitamin D and angiotensin
 364 converting enzyme 2: Implications for a potential treatment for COVID-19. Rev Med
 365 Virol. 2020;1–6.
- 366 7. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among
 367 free-living healthy young adults. Am J Med. 2002;112:659-662
- Christakos S, Hewison M, Gardner DG, Wagner CL, Sergeev IN, Rutten E, Pittas
 AG, Boland R, Ferrucci L, and Bikleet DD. Vitamin D: beyond bone. Ann N Y Acad
 Sci. 2013;1287:45–58.
- Zemb P, Bergman P, Camargo CA, Jr, Cavalier E, Cormier C, Courbebaisse M,
 Hollis B, Joulia F, Minisola S, Pilz S, Pludowski P, Schmitt F, Zdrenghea M, and

- Souberbielle JC. Vitamin D deficiency and the COVID-19 pandemic. J Glob
 Antimicrob Resist. 2020 Sep; 22: 133–134
- 375 10. Tsiaras WG and Weinstock MA. Factors influencing vitamin D status. Acta Derm
 376 Venereol 2011 Mar;91(2):115-24
- 377 11. Kim YA, Cho YJ. The association between visceral fat, subcutaneous fat and
 378 serum 25-hydroxyvitamin D3 levels. Obesity Medicine 13 (2019) 29–33
- 379 12. Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer outcome? Lancet
 380 Diabetes Endocrinol 2020 Jul;8(7):570
- 381 13. Greiller CL and Martineau AR. Modulation of the Immune Response to Respiratory
 382 Viruses by Vitamin D. Nutrients 2015, 7, 4240-4270
- 383 14. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-
- 384 Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ,
- Janssens W, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees
- 386 JR, Simpson S Jr, Stelmach I, Trilok Kumar G, Urashima M and Camargo CA Jr.
- 387 Vitamin D supplementation to prevent acute respiratory tract infections: systematic
 388 review and meta-analysis of individual participant data BMJ 2017;356:i6583
- 15. D'Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, Keller
 F,Cantù M. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with
 Positive PCR for SARS CoV-2. Nutrients. 2020 May 9; 12:1359.
- 392 16. Meltzer DO, Best TJ, PhD, Zhang H, Vokes T, Arora V and Solway J. Association
 393 of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test
 394 Results. JAMA Network Open. 2020;3(9):e2019722
- 395 17. Raisi-Estabragh Z, McCracken C, Bethell MS, Cooper J, Cooper C, Caulfield MJ,
 396 Munroe PB, Harvey NC, Petersen SE. 2020 Greater risk of severe COVID-19 in

- 397 Black, Asian and Minority Ethnic populations is not explained by cardiometabolic,
- 398 socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326
- cases from the UK Biobank. J Public Health (Oxf) Aug 18;42(3):451-460
- 400 18. Radujkovic A, Hippchen T, Tiwari-Heckler S, Dreher S, Boxberger M, and Merle U
- 401 (2020) Vitamin D deficiency and outcome of COVID 19 patients. Nutrients 12:2757.
 402 https://doi.org/10.3390/nu12092757
- 403 19. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A,
- 404 González-Díaz A, Márquez-Salinas A, Fermín-Martínez CA, Naveja JJ,
- 405 Aquilar-Salinas CA. Predicting Mortality Due to SARS-CoV-2: A Mechanistic
- 406 Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. J
- 407 Clin Endocrinol Metab. 2020 Aug 1;105(8):dgaa346. doi:
 408 10.1210/clinem/dgaa346.
- 20. Tzung-Dau Wang, et. al. 2009, Relations of Epicardial Adipose Tissue Measured
 by Multidetector Computed Tomography to Components of the Metabolic
 Syndrome Are Region-Specific and Independent of Anthropometric Indexes and
 Intraabdominal Visceral Fat. J Clin Endocrinol Metab, 94(2):662–669.
- 413 21. Michael T. Lu, MD. 2007, Reformatted Four-Chamber and Short-Axis Views of the
 414 Heart Using Thin Section (≤2 mm) MDCT Images. Acad Radiol 2007; 14:1108–
 415 1112
- 416 22. Angela Gallina Bertaso, 2013. Epicardial Fat: Definition, Measurements and
 417 Systematic Review of Main Outcomes. DOI: 10.5935/abc.20130138
- 418 23. Evans RM and Lippman SM. Shining Light on the COVID-19 Pandemic: A Vitamin
 419 D Receptor Checkpoint in Defense of Unregulated Wound Healing. Cell
 420 Metabolism. 2020 Nov 3; 32(5):704-709

- 421 24. McCartney DM, O'Shea PM, Faul JL, Healy MJ, Byrne G, Griffin TP, Walsh JB,
 422 Byrne DG and Kenny RA. Vitamin D and SARS-CoV-2 infection—evolution of
 423 evidence supporting clinical practice and policy development. A position statement
 424 from the Covit-D Consortium. Irish Journal of Medical Science (1971 -)
 425 https://doi.org/10.1007/s11845-020-02427-9
- 426 25. Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A,
 427 Madhavan MV, Nair N, Babalyan V, Hutchings N, Napoli N, Accili D, Binkley N,
 428 Landry DW and Giustina A. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and
- 429 COVID-19. Eur J Endocrinol. 2020 Nov;183(5):R133-R147
- 430 26. Brown, R. 2020. Vitamin D deficiency: a factor in COVID-19, progression, severity
- 431 and mortality? An urgent call for research. Mito Fit Preprint Arch., 1-29., (28.
- 432 Schwalfenberg, G. K. 2011. A review of the critical role of vitamin D deficiency.
 433 Mol. Nutr. Food Res. 55, 96-108.28
- 434 27. Grant W, L. H. 2020. Evidence that Vitamin D Supplementation Could Reduce Risk
 435 of Influenza and COVID-19 Infections and Deaths. Nutrients, 1-19
- 436 28. Wei Shan Hoong C, Huilin K, Cho S, Meyyur Aravamudan V and Hui Xian Lin J.
 437 Are Adequate Vitamin D Levels Helpful in Fighting COVID-19? A Look at the
 438 Evidence. Horm Metab Res. 2020 Nov; 52(11):775-783
- 439 29. E. Laird, J. R. 2020. Vitamin D and Inflammation: Potential Implications for Severity
 440 of Covid-19. Irish Medical Journal, 81.
- 30. Jeffery, L. 2009. 1,25-dihydroxyvitamin D3 and interleukin-2 combine to inhibit T
 cell production of inflammatory cytokines and promote development of regulatory T
 cells expressing CTLA-4 and FoxP3. Journal of Immunology, 5458–5467.
- 31. Baeke, F., Takiishi, T. 2010. Vitamin D: modulator of the immune system. Current
 Opinion in Pharmacology, 482–496.

32. Maghbooli Z, S. M. 2020. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at
least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-

448 19 infection. PLoS One, 1-13.

- 33. Carpagnano G, D. L. 2020. Vitamin D deflciency as a predictor of poor prognosis in
 patients with acute respiratory failure due to COVID-19. Journal of Endocrinological
 Investigation, 1-7
- 452 34. Weir, E. 2020. Does vitamin D deficiency increase the severity of COVID-19?
 453 Clinical Medicine, 1-2.
- 454 35. Rodriguez Tort, A. 2020. La deficiencia de vitamina D es un factor de riesgo de 455 mortalidad en pacientes con COVID-19. Rev Sanid Milit Mex, 106-113.
- 456 36. Pan et al.2020. The impact of ethnicity on clinical outcomes in COVID-19: A
 457 systematic review. EClinicalMedicine, 1-8.
- 37. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, Silva CBR,
 Franco AS, Macedo MB, MD, Dalmolin HHH, Baggio J, Balbi GGM, Reis BZ,
 Antonangelo L, Caparbo VF, Gualano B, Pereira RMR, MD. Effect of Vitamin D3
 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe
 COVID-19: A Multicenter, Double-blind, Randomized Controlled Trial. doi:
 10.1101/2020.11.16.20232397
- 38. Márquez-Salinas A, Fermín-Martínez CA, Antonio-Villa NE, Vargas-Vázquez A, C.
 Guerra E, Campos-Muñoz A, Zavala-Romero L, Mehta R, Bahena-López JP, OrtizBrizuela R, González-Lara MF, Roman-Montes CM, Martinez-Guerra BA, Ponce
 de Leon A, Sifuentes-Osornio J, Gutiérrez-Robledo LM, Aguilar-Salinas CA, BelloChavolla OY medRxiv 2020.11.03.20225375; doi: 10.1101/2020.11.03.20225375

469 TABLES

- 470 **Table 1.** Clinical characteristics, imaging findings and severity scores in patients with
- 471 COVID-19, comparing cases with and without low vitamin D levels.

	Vitamin D	Vitamin D	
Parameter	[>20 ng/mL]	[≤20 ng/mL]	P-value
	(n=300)	(n=251)	
Age (years)	53.0 (±14.92)	51.0 (±12.60)	0.088
Male Sex (%)	219 (73%)	136 (54.2%)	<0.001
Low-Socioeconomic Status (%)	203 (67.66%)	172 (68.5%)	0.902
Critical outcome (%)	85 (28.3)	81 (32.3)	0.363
Intubation (%)	53 (17.6)	40 (15.9)	0.670
Mortality (%)	57 (19)	59 (23.5)	0.23
Arterial Hypertension (%)	83 (27.94%)	89 (35.9%)	0.058
Type 2 diabetes (%)	68 (22.9%)	78 (31.6%)	0.031
Time since diagnosis (years)	9.8 (±7.8)	9.20 (±7.5)	0.831
Obesity (%)	118 (39.9%)	111 (44.9%)	0.269
Smoking status (%)	15 (5.8%)	12 (5.8%)	0.789
CKD (%)	6 (2.0%)	12 (4.9%)	0.111

CVD (%)	6 (2.0%)	10 (4.0%)	0.258
Cirrhosis (%)	0 (0%)	3 (1.21%)	0.186
BMI (kg/m2)	29.83 (±4.92)	30.32 (±6.56)	0.343
Respiratory Rate (rpm)	28.52 (±12.40)	28.31 (±9.11)	0.821
Heart Rate (bpm)	102.31 (±18.2)	101.85 (±18.5)	0.771
Systolic Arterial Pressure (mmHg)	120 (110-131)	123 (110-135)	0.264
Diastolic Arterial Pressure (mmHg)	76 (70-80)	74 (67-81)	0.322
Oxygen saturation (%)	82.65 (±11.4)	79.89 (±13.4)	0.010
C-reactive protein	14.93 (9.02- 23.20)	13.6 (6.37-21.76)	0.052*
Glucose levels (mg/dL)	149.7 (±85.73)	163.6 (±97.98)	0.0805*
HbA1c (%)	6.10 (5.8-7.05)	6.85 (6.0-9.6)	0.0040
Triglycerides (mg/dL)	149 (114-192)	140 (110-179)	0.2907
HDL-C (mg/dL)	32.7 (±15.25)	33.3 (±10.71)	0.9111
LDL-C (mg/dL)	95.9 (±57.38)	75.1 (±34.74)	0.2818
Total Cholesterol (mg/dL)	159.5 (±60.93)	135.7 (±44.23)	0.2658

Hemoglobin (%)	15.45 (1.85)	17.42 (22.99)	0.1794
Platelet Count ()	230.97 (90.89)	236.53 (103.83)	0.5089
Lymphocytes	8.91 (4.35)	9.16 (4.93)	0.5287
Neutrophils	6435.0 (4699.1)	6336.8 (5227.20)	0.8187
Serum Creatinine (mg/dL)	0.95 (0.79-1.15)	0.91 (0.74-1.16)	0.6451
Ferritin (mg/dl)	656.0 (323.3- 1138.7)	553.3 (284.7-959.7)	0.06174*
D-Dimer	629 (401-1049)	821 (454-1376)	0.00071
Protrombin	11.4 (10.8-12.4)	11.4 (10.6-12.5)	0.3642
Fibrinogen	697.0 (556.5- 854.5)	672 (482-789)	0.01406
BUN	18.1 (11.6)	20.7 (17.7)	0.0539*
AST	42.6 (30.5-62.5)	41.4 (30.1-64.7)	0.6787
ALT	35.9 (23.7-55-1)	33.50 (23.8-58.2)	0.6321
Albumin	3.8 (3.44-4.01)	3.6 (3.26-3.96)	0.0024
Lactate dehydrogenase	361 (291-466)	374 (278.5-498.5)	0.7565
СК	116 (64-236)	104.5 (55-225.3)	0.1976
Procalcitonin	0.270 (0.06-	0.32 (0.15-1.22)	0.2991

	0.57)		
Symptoms (n)	5 (3-5)	4 (3-5)	0.107
Comorbidities (n)	1 (0-1)	1 (0-2)	0.001
Time hospitalized (days)	6 (3-10)	6 (3-10)	0.995
CT findings			
Epicardial fat (%)	9.3 (7.3-11.7)	10 (8.2-12.2)	0.011
Pericardial fat (%)	185 (61.7)	145 (57.8)	0.407
Subthoracic fat (%)	15 (10-21)	17 (12-24)	0.010
Ground Glass Opacity (%)	297 (99)	248 (98)	0.710
Consolidations (%)	158 (53.6)	136 (54.2)	0.781
GGO + Consolidations (%)	158 (53.6)	136 (54.2)	0.721
Lobules afected 1 2 3	34 (11.3) 82 (32.7) 132 (52.6)	34 (11.3) 125 (41.7) 140 (46.6)	0.178
Hepatic Steatosis (%)	99 (33)	90 (35.9)	0.539
Severity Scores			
NEWS (pts)	8 (6-9)	8 (7-9)	0.733
QSOFA (pts)	1 (1-1)	1 (1-1)	0.329

CURB-65 (pts)	1 (0-2)	1 (0-2)	0.347

472

474 **Table 2.** Multiple linear regression model to identify determinants of Vitamin D levels in

Model	Parameter	β- coefficient	95%CI	t	P- value
	Intercept	3.515	3.177-3.853	20.426	<0.001
	Male Sex	0.168	0.097 -0.238	4.668	<0.00
	Ultrasensitive troponin	-0.033	-0.0630.002	-2.124	0.034
Vitamin D $R^2=0.1091$	D-dimer	-0.060	-0.1000.020	-2.951	0.003
	C-reactive protein	0.065	0.026-0.103	3.265	0.001
	Epicardial fat	-0.126	-0.2220.031	-2.599	0.010
	Type 2 diabetes	-0.072	-0.147 – 0.004	-1.871	0.062

475 patients with COVID-19.

476

Table 3. Cox proportional risk regression models to predict mortality related to COVID-19
using Vitamin D levels adjusted for covariates. Model 1: Unadjusted, Model 2: Adjusted for
age, gender, body-mass index (BMI) and C-reactive protein (CRP), Model 3: Model 2
adjusted for chronic kidney disease (CKD), epicardial fat and type 2 diabetes (T2D.

Model	Parameter	β- coefficient	HR (95%CI)	P-value
Model 1 c-statistic=0.566	Vitamin D	-0.036	0.965 (0.942-0.988)	0.003
	Vitamin D	-0.043	0.938 (0.934-0.983)	0.001
	Age	0.037	1.037 (1.022-1.052)	<0.001
Model 2 c-statistic=0.694	Male gender	0.787	2.196 (1.373-3.512)	0.001
	BMI	0.038	1.039 (1.005-1.073)	0.024
	CRP	0.004	1.004 (1.002-1.007)	<0.001
	Vitamin D	-0.039	0.962 (0.935-0.989)	0.006
	СКД	0.301	0.749 (0.276-2.030)	0.570
Model 3	T2D	0.325	1.384 (0.882-2.170)	0.157
c-statistic=0.702	Ultrasensitive			
	cardiac	0.170	1.185 (1.002-1.403)	0.048
	troponin			
	D-dimer	0.003	1.003 (0.804-1.252)	0.980


	Oxygen saturation	-0.026	0.975 (0.960-0.990)	0.001
	Epicardial fat thickness	0.669	1.952 (0.501-7.607)	0.335
482				

484 **Table 4:** Causal mediation analyses predicting the effect of Vitamin D levels (E) mediated by elevated D-dimer, ultrasensitive cardiac

troponins or low SpO2 (M) on severe COVID-19 and mortality (Y), adjusted by gender, age, BMI and epicardial fat.


486 **Abbreviations:** ACME: average causal mediation effects; ADE: average direct effects; SpO2: Oxygen saturation levels.


			ACME	ADE	Total Effect	Proportion
Outcome (Y)	Efector (E)	Mediator	ACME	ADE		Mediated
	(M)	(95%CI)	(95%CI)	(95%CI)	(95%CI)	
		D-dimer	-0.035	-0.144	-0.179	19.3%
		D-umer	(-0.069,-0.010)	(-0.164, -0.10)	(-0.188,-0.050)	(9.5-77.0%)
COVID-19	Vitamin D	Ultrasentivie	-0.047	-0.133	-0.181	26.2%
Mortality	Vitamin D	cardiac troponins	(-0.085, -0.020)	(-0.150, -0.020)	(-0.183, -0.060)	(15.0-73.0%)
		SpO2	-0.037	-0.144	-0.181	20.3%
		σροε	(-0.066, -0.010)	(-0.159, -0.030)	(-0.186,-0.050)	(9.7-64.0%)



488 FIGURE LEGENDS

490 Figure 1. Boxplots comparing Vitamin D levels according to the need for invasive mechanical ventilation (IVM) or lethal COVID-19






493


494 Figure 2. Post-estimation simulation of Vitamin D levels to predict COVID-19 lethality, adjusted for age, sex, BMI, C-reactive protein,

495 epicardial fat, D-dimer, oxygen saturation, T2D, and CKD using Vitamin D cut-offs of <20ng/dL (A) and ≤12ng/mL





499 Figure 3. Model-based causal mediation analyses to investigate the role of Vitamin D on COVID-19 mortality mediated by D-dimer



510 Supplementary Material

- 511 **Table 1.** Clinical characteristics, imaging findings and severity scores in patients with COVID-19, comparing cases with and without
- 512 severely low vitamin D levels (vitamin D deficiency).

Parameter	Vitamin D [>12 ng/mL] (n=494)	Vitamin D [≤12 ng/mL] (n=57)	P-value
Age (years)	51.6 (13.7)	54.9 (13.9)	0.0865
Male Sex (%)	327 (66.2)	28 (49.2)	0.01626
Severe outcome (%)	142 (28.7)	24 (42.1)	0.0537
Intubation (%)	83 (16.8)	10 (17.4)	0.981
Letality (%)	95 (19.23)	21 (36.8)	0.0035
Low-Socioeconomic Status (%)	336 (68)	39 (68.3)	0.921
Arterial Hypertension (%)	150 (30.7)	22 (38.6)	0.293
Type 2 diabetes (%) Time since diagnosis (years)	124 (25.5) 9.1 (7.14)	22 (38.6) 11.6 (9.78)	0.0512 0.297
Obesity (%)	204 (41.9)	25 (44.6)	0.8008
Smoking status (%)	26 (6.25)	1 (1.75)	0.921
CKD (%)	15 (3.10)	3 (5.26)	0.637
CVD (%)	14 (2.88)	2 (3.51)	0.921
Cirrhosis (%)	2 (0.41)	1 (1.75)	0.7256
BMI (kg/m2)	30.0 (5.29)	30.5 (8.76)	0.7227
Respiratory Rate (rpm)	28.4 (11.4)	28.7 (6.9)	0.7946

Heart Rate (bpm)	102.5 (18.3)	98.8 (18.3)	0.1545
Systolic Arterial Pressure (mmHg)	122 (110-132)	120 (110-136)	0.3157
Diastolic Arterial Pressure (mmHg)	75 (70-80)	73 (66-80)	0.242
Oxygen saturation (%)	81.7 (12.2)	78.8 (13.8)	0.1302
C-reactive protein	14.7 (7.8-21.9)	12.8 (6.7-27.9)	0.8042

Parameter	Vitamin D [>12 ng/mL] (n=494)	Vitamin D [≤12 ng/mL] (n=57)	P-value
Glucose levels (mg/dL)	152 (85.8)	185 (129.7)	0.0689
HbA1c (%)	6.3 (5.9-7.6)	8.0 (6.3-10.6)	0.00312
Triglycerides (mg/dL)	141 (111-183)	164 (118-237)	0.07487
HDL-C (mg/dL)	33 (13.4)	33 (7.78)	0.981
LDL-C (mg/dL)	84.7 (45.8)	80.3 (55.0)	0.887
Total Cholesterol (mg/dL)	147.7 (50.9)	135 (67.7)	0.7396
Hemoglobin	16.1 (12.3)	18.4 (28.9)	0.5584
Platelet Count	232.1 (95.5)	245.8 (108.9)	0.364
Leucocytes	8.96 (4.5)	9.62 (5.7)	0.4071

Symptoms (n)	4	(3-5) 4 (3-5)	0.162
Parameter	[>12	min D Vitamin D ng/mL] [≤12 ng/mL] =494) (n=57)	P-value
Procalcitonina	0.27 (0.07-0.56)	3.045 (3.03-3.88)	0.034
СК	110 (61-229)	103 (55-250)	0.6239
DHL	358 (283-476)	402 (316-521)	0.06721
Albumin	3.72 (3.38-4.00)	3.34 (2.93-3.77)	0.001
ALT	34.9 (23.9-56.8)	33.5 (22.3-53.6)	0.5808
AST	41.9 (30.3-62.72)	42.6 (30.3-65.1)	0.6716
BUN	18.8 (13.9)	23.9 (20.5)	0.0711
Fibrinogen	680 (526-820)	705 (464-896)	0.8438
Protrombin	11.4 (10.8-12.5)	11.4 (10.6-12.5)	0.4982
D-Dimer	670 (413-1,178)	949 (567-1,803)	0.0025
Ferritin (mg/dl)	613 (287-1.069)	610 (389-984)	0.9173
Serum Creatinine (mg/dL)	0.93 (0.77-1.15)	0.90 (0.75-1.19)	0.6636
Neutrophils	6300.9 (4777.395)	7157.1 (6186.3)	0.3161

Comorbid conditions (r	n) 1 (1-2)	2 (1-3)	0.042
Time hospitalized (days	s) 6 (3-10)	6 (3-8)	0.489
CT findings			
Epicardial fat (%)	9.7 (7.7-11.8)	10.2 (8.0-12.7)	0.105
Pericardial fat (%)	296 (59.4)	34 (59.6)	0.942
Subthoracic fat (%)	16 (11-22)	17 (12-25)	0.225
Ground Glass Opacity (%) 488 (98.8)	57 (100)	0.747
Consolidation (%)	258 (52.2)	36 (63.1)	0.162
GGO + Consolidation (9	%) 257 (52%)	36 (63.1)	0.154
Lobules afected 1 2 3	65 (13.1) 190 (38.5) 239 (48.4)	7 (12.3) 17 (29.8) 33 (57.8)	0.553
Hepatic Steatosis (%)	172 (34.8)	17 (29.8)	0.545
Severity Scores			
NEWS (pts)	8 (6-9)	8 (7-9)	0.694
QSOFA (pts)	1 (1-2)	1 (1-2)	0.785
CURB-65 (pts)	1 (0-2)	1 (0-2)	0.341